[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360333-105":59,"doc-detail-360333-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","niclosamide-attenuates-skin-cancer-progression-through-suppression-of-key-oncogenic-pathways-integrated-in-vivo-and-in-silico-mechanistic-insights","Niclosamide attenuates skin cancer progression through suppression of key oncogenic pathways: integrated in vivo and in-silico mechanistic insights","","Niclosamide, an FDA-approved anti-helminthic drug, is evaluated for chemopreventive activity in a DMBA/TPA-induced mouse model of skin carcinogenesis, using integrated biological and network-based analyses. Mice receive niclosamide at 15, 30, and 45 mg/kg, with healthy, disease, and standard therapy controls. Niclosamide reduces tumor volume dose-dependently, suppresses TNF-α, IL-6, and IL-1β, restores MDA/SOD/GSH balance, activates caspase-3-mediated apoptosis, and downregulates VEGF angiogenesis signaling. Protein-protein interaction network analysis identifies two functional clusters and hub genes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/niclosamide-attenuates-skin-cancer-progression-through-suppression-of-key-oncogenic-pathways-integrated-in-vivo-and-in-silico-mechanistic-insights/360333/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/niclosamide-attenuates-skin-cancer-progression-through-suppression-of-key-oncogenic-pathways-integrated-in-vivo-and-in-silico-mechanistic-insights/360333.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What skin cancer model and treatment schedule were used to test niclosamide?","Question",{"text":112,"@type":113},"The study used a DMBA/TPA-induced mouse model of skin carcinogenesis. Mice were treated with niclosamide at 15, 30, and 45 mg/kg and compared with healthy, disease, and standard therapy controls.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biological markers did niclosamide affect in treated mice?",{"text":117,"@type":113},"Niclosamide suppressed inflammatory cytokines (TNF-α, IL-6, IL-1β), restored oxidative stress and antioxidant balance (MDA, SOD, GSH), activated apoptosis signaling (caspase-3 and Bax/Bcl-2), and downregulated angiogenesis marker VEGF.",{"name":119,"@type":110,"acceptedAnswer":120},"How did network pharmacology support the proposed anticancer mechanism?",{"text":121,"@type":113},"A protein-protein interaction network constructed from eleven relevant genes revealed two functional clusters linked to inflammation, apoptosis, and redox homeostasis, with hub genes including TNF, IL6, CASP3, and GPX1 highlighting interactions among pathways affected by niclosamide.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360333,1790188898,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Oraibi etal. BMC Cancer (2026) 26:698 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15999-z](https://doi.org/10.1186/s12885-026-15999-z)  \nRESEARCH Open Access  \nNiclosamide attenuates skin cancer progression through suppression of key oncogenic pathways: integrated in vivo and in-silico mechanistic insights  \nAmjad Ibrahim Oraibi1*, Mahmood Al-Ibadah2, Ali Al-Samydai3, Muataz Naeem Hussein4, Hany Akeel Al-hussaniy5, Maryam Saleem6, Ali Almukram7, MulugetaTesemma8*, Esmael M. Alyami9,10, Ohoud A. Alghamdi 12,  \nAhmed Hamza Al-Shammari11, Gehan M. Elossaily 14,15 and Omar A. Almohammed 13*  \nAbstract  \nNiclosamide, an FDA-approved anti-helminthic drug, has attracted attention for its potential to target multiple cancer-related pathways. This study evaluated the chemopreventive effect of niclosamide in a DMBA/TPA-induced mouse model of skin carcinogenesis and explored its mechanisms using integrated biological and network-based approaches. Mice were treated with niclosamide at 15, 30, and 45 mg/kg and compared with healthy, disease, and standard therapy controls. Tissue and serum analyses were conducted to measure markers of inflammation (TNF-α, IL-6, IL-1β), oxidative stress (MDA, SOD, GSH), apoptosis (caspase-3, Bax/Bcl-2), and angiogenesis (VEGF) . Niclosamide reduced tumor volume in a dose-dependent manner, suppressed inflammatory cytokines, restored antioxidant levels, activated apoptotic signaling, and downregulated VEGF expression. A protein-protein interaction network was constructed using eleven experimentally relevant genes to identify key regulatory modules. Network topology and enrichment analysis revealed two functional clusters associated with inflammation, apoptosis, and redox homeostasis. Hub genes such as TNF, IL6, CASP3, and GPX1 highlighted potential interactions among pathways affected by niclosamide. Thus, these findings suggest that niclosamide may exert anticancer effects by modulating interconnected pathways related to inflammation, oxidative stress, apoptosis, and angiogenesis, supporting its potential for further investigation as a repurposed therapeutic candidate for skin cancer.  \nKeywords Niclosamide, Skin cancer, Drug repurposing, DMBA/TPA-induced skin cancer model, Network Pharmacology  \n*Correspondence:  \nAmjad Ibrahim Oraibi [amjadibrahim@uomanara.edu.iq](amjadibrahim@uomanara.edu.iq)[ ](amjadibrahim@uomanara.edu.iq)MulugetaTesemma [mulugetatesemmarer@gmail.com](mulugetatesemmarer@gmail.com)[ ](mulugetatesemmarer@gmail.com)Omar A. Almohammed  \noalmohammed@KSU. EDU. SA; [oalmohammed@ksu.edu.sa](oalmohammed@ksu.edu.sa)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026, modified publication 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercialNoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://cre](http://cre)[ativecommons.org/licenses/by-nc-nd/4.0/](ativecommons.org/licenses/by-nc-nd/4.0/.)[.](ativecommons.org/licenses/by-nc-nd/4.0/.)  \nOraibi et al. BMC Cancer (2026) 26:698  \nIntroduction  \nSkin cancer is a significant global health concern, accounting for millions of new cases each yea","cbCaimV8TjaIrsNQ","https://ap.wps.com/l/cbCaimV8TjaIrsNQ","pdf",2333083,15,"English","# Abstract\n# Keywords\n# Introduction\n## Skin cancer overview\n## Drug repurposing as a strategy\n## Rationale for niclosamide","[{\"question\":\"What skin cancer model and treatment schedule were used to test niclosamide?\",\"answer\":\"The study used a DMBA/TPA-induced mouse model of skin carcinogenesis. Mice were treated with niclosamide at 15, 30, and 45 mg/kg and compared with healthy, disease, and standard therapy controls.\"},{\"question\":\"Which biological markers did niclosamide affect in treated mice?\",\"answer\":\"Niclosamide suppressed inflammatory cytokines (TNF-α, IL-6, IL-1β), restored oxidative stress and antioxidant balance (MDA, SOD, GSH), activated apoptosis signaling (caspase-3 and Bax/Bcl-2), and downregulated angiogenesis marker VEGF.\"},{\"question\":\"How did network pharmacology support the proposed anticancer mechanism?\",\"answer\":\"A protein-protein interaction network constructed from eleven relevant genes revealed two functional clusters linked to inflammation, apoptosis, and redox homeostasis, with hub genes including TNF, IL6, CASP3, and GPX1 highlighting interactions among pathways affected by niclosamide.\"}]","Niclosamide attenuates skin cancer progression through suppression of key oncogenic pathways: integrated in vivo and in-silico mechanistic insights | PDF",1790139693,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6ee811f27044914bb81d4d5ffa2952a.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3616f29979724831b03391774618ff4a.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30cb2037260e11b1f751d9c471317186.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63142477ee5b54eacf71761bf3239af4.webp",980,1306]